{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Khaki AR"],"funding":["NCATS NIH HHS","National Cancer Institute","NCI NIH HHS","Wellcome Trust"],"pagination":["464-472"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8169524"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(3)"],"pubmed_abstract":["<h4>Background</h4>While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers (except for PD-L1).<h4>Objective</h4>We aimed to develop a prognostic model for overall survival (OS) in patients receiving 1L ICIs for advanced urothelial cancer (aUC) in a multicenter cohort study.<h4>Design, setting, and participants</h4>Patients treated with 1L ICIs for aUC across 24 institutions and five countries (in the USA and Europe) outside clinical trials were included in this study.<h4>Outcome measurements and statistical analysis</h4>We used a stepwise, hypo"],"journal":["European urology oncology"],"pubmed_title":["A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors."],"pmcid":["PMC8169524"],"funding_grant_id":["T32 CA009515","PS3416","UL1 TR001863","UL1 TR002319"],"pubmed_authors":["Agarwal N","Kumar V","Lythgoe MP","Yu EY","Alva A","Zakharia Y","Santos V","Zakopoulou R","Drakaki A","Grivas P","Liu S","Carril-Ajuria L","De Kouchkovsky I","Castellano D","Gartrell BA","Murgic J","Li A","Nelson A","Tripathi A","Isaacsson Velho P","Joshi M","Lyman GH","Frobe A","Moses M","Morales-Barrera R","Park J","Koshkin V","Jain J","Hahn N","Alonso Buznego L","Diamantopoulos LN","Stewart T","Galsky MD","Bilen MA","Bamias A","Sonpavde G","Miller NJ","Barata P","Khaki AR","Rodriguez-Vida A","Duran I","Pinato DJ","Sankin A","Hoimes CJ","Shreck E","Shankaran V","Devitt M"],"additional_accession":[]},"is_claimable":false,"name":"A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.","description":"<h4>Background</h4>While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers (except for PD-L1).<h4>Objective</h4>We aimed to develop a prognostic model for overall survival (OS) in patients receiving 1L ICIs for advanced urothelial cancer (aUC) in a multicenter cohort study.<h4>Design, setting, and participants</h4>Patients treated with 1L ICIs for aUC across 24 institutions and five countries (in the USA and Europe) outside clinical trials were included in this study.<h4>Outcome measurements and statistical analysis</h4>We used a stepwise, hypo","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-04T20:15:40.678Z","creation":"2025-04-04T20:15:40.678Z"},"accession":"S-EPMC8169524","cross_references":{"pubmed":["33423945"],"doi":["10.1016/j.euo.2020.12.006"]}}